The Small Molecule JAK1/JAK2 Inhibitor INCB16562 Shows Single Agent Activity and Strongly Synergizes with Bcl-2 Inhibitors in Lymphoma

被引：0
|
作者：
Derenzini, Enrico [1 ]
Lemoine, Manuela [1 ]
Brighenti, Elisa [2 ]
Davis, Richard Eric [1 ]
Zinzani, Pier Luigi [3 ]
Younes, Anas [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA
[2] Univ Bologna, Dept Radiol & Histocytopathol Clin Sci, Bologna, Italy
[3] Univ Bologna, Dept Hematol Oncol L&A Seragnoli, Bologna, Italy
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1175 / 1175
页数：1
相关论文
共 42 条
  • [21] BCL2A1 is expressed in myelofibrosis specimens and JAK2-mutated UKE-1 cells, yet does not inhibit synergistic cell killing by BCL-XL inhibitor navitoclax plus JAK1/2 inhibitors, including ruxolitinib
    Refici, Marion
    Yang, Ziping
    Riehm, Jacob
    Phillips, Darren
    Souers, Andrew
    Harb, Jason
    CANCER RESEARCH, 2022, 82 (12)
  • [22] 12-WEEK RESULTS OF A PHASE 2B DOSE-RANGING STUDY OF LY3009104 (INCB028050), AN ORAL JAK1/JAK2 INHIBITOR, IN COMBINATION WITH TRADITIONAL DMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Keystone, E.
    Taylor, P.
    Genovese, M.
    Schlichting, D.
    Beattie, S.
    Gaich, C.
    Gort, R. Fidelus
    Luchi, M.
    Macias, W. L.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 152 - 153
  • [23] Novel small molecule inhibitors of Jak2/STAT3 pathway: design, structure-activity relationship, and oral bioavailability
    Priebe, W.
    Fokt, I.
    Szymanski, S.
    Bao, Y.
    Conrad, C.
    Chakraborty, A.
    Abbruzzese, J.
    Guha, S.
    Myers, J.
    Madden, T.
    EJC SUPPLEMENTS, 2006, 4 (12): : 169 - 169
  • [24] Selective pharmacologic targeting of CTPS1 shows single-agent activity and synergizes with BCL2 inhibition in aggressive mantle cell lymphoma
    Durand, Romane
    Bellanger, Celine
    Kervoelen, Charlotte
    Tessoulin, Benoit
    Dousset, Christelle
    Menoret, Emmanuelle
    Asnagli, Helene
    Parker, Andrew
    Beer, Philip
    Pellat-Deceunynck, Catherine
    Chiron, David
    HAEMATOLOGICA, 2024, 109 (08) : 2574 - 2584
  • [25] The combination of ruxolitinib and Bcl-2/Mcl-1 inhibitors has a synergistic effect on leukemic cells carrying a SPAG9::JAK2 fusion
    Mayumi, Azusa
    Tomii, Toshihiro
    Kanayama, Takuyo
    Mikami, Takashi
    Tanaka, Kuniaki
    Ueno, Hiroo
    Yoshida, Hideki
    Kato, Itaru
    Kawamura, Machiko
    Nakahata, Tatsutoshi
    Takita, Junko
    Hosoi, Hajime
    Imamura, Toshihiko
    CANCER GENE THERAPY, 2022, 29 (12) : 1930 - 1938
  • [26] The combination of ruxolitinib and Bcl-2/Mcl-1 inhibitors has a synergistic effect on leukemic cells carrying a SPAG9::JAK2 fusion
    Azusa Mayumi
    Toshihiro Tomii
    Takuyo Kanayama
    Takashi Mikami
    Kuniaki Tanaka
    Hiroo Ueno
    Hideki Yoshida
    Itaru Kato
    Machiko Kawamura
    Tatsutoshi Nakahata
    Junko Takita
    Hajime Hosoi
    Toshihiko Imamura
    Cancer Gene Therapy, 2022, 29 : 1930 - 1938
  • [27] Targeting of PIM Kinases Shows Single Agent Efficacy and Synergizes With BCL2 Inhibitors in Diffuse Large B Cell Lymphoma of the ABC Subtype
    Tarantelli, Chiara
    Kayali, Omar
    Civanelli, Elisa
    Cascione, Luciano
    Mensah, Afua Adjeiwaa
    Folloni, Chiara
    Arribas, Alberto J.
    Rinaldi, Andrea
    Cmiljanovic, Vladimir
    Mondello, Patrizia
    Bertoni, Francesco
    HEMATOLOGICAL ONCOLOGY, 2025, 43 (02)
  • [28] Topical ruxolitinib 1.5% (JAK1/JAK2 inhibitor) improves clinical and patient-reported outcomes in moderate to severe chronic hand dermatitis: Data from a small open-label trial
    Smith, Hannah D.
    Lally, Jag S.
    Moy, Alison
    Ryan-Wolf, Julie
    De Benedetto, Anna
    JEADV CLINICAL PRACTICE, 2024, 3 (04): : 1016 - 1026
  • [29] Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-XL 1(-)-gossypol] against diffuse large cell lymphoma
    Mohammad, RM
    Wang, SM
    Aboukameel, A
    Chen, B
    Wu, XH
    Chen, JY
    Al-Katib, A
    MOLECULAR CANCER THERAPEUTICS, 2005, 4 (01) : 13 - 21
  • [30] PHASE 1 STUDY OF A NOVEL ORAL JAK2 INHIBITOR, SB1518, IN PATIENTS WITH RELAPSED LYMPHOMA: EVIDENCE OF CLINICAL AND BIOLOGIC ACTIVITY IN MULTIPLE LYMPHOMA SUBTYPES
    Younes, A.
    Fanale, M.
    Mclaughlin, P.
    Copeland, A.
    Faria, S. De Castro
    Zhu, J.
    ANNALS OF ONCOLOGY, 2011, 22 : 136 - 137
12345